Needham Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

Benzinga · 1d ago
Needham analyst Gil Blum reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.